Clinical impact of sarcopenia assessment in patients with liver cirrhosis

References

• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis European working group on sarcopenia in older people 2 (EWGSOP2), and the extended group for EWGSOP2. Age Ageing. 2019;48:16–31.
   PubMed Web of Science ®Google Scholar
• Montano-Loza AJ, Meza-Junco J, Prado CMM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166-173.
   PubMedGoogle Scholar
• Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clin Liver Dis. 2012;16:95–131. NIH Public Access.
   PubMed Web of Science ®Google Scholar
• Tapper EB, Zhang P, Garg R, et al. Body composition predicts mortality and decompensation in compensated cirrhosis patients: a prospective cohort study. JHEP Rep. 2020;2:100061.
   PubMedGoogle Scholar
• Fan ST, lo CM, Lai E, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med. 1994;331:1547–1552.
   PubMed Web of Science ®Google Scholar
• Takagi K, Yagi T, Yoshida R, et al. Sarcopenia and American society of anesthesiologists physical status in the assessment of outcomes of hepatocellular carcinoma patients undergoing hepatectomy. Acta Med Okayama. 2016;70:363–370.
   PubMed Web of Science ®Google Scholar
• Norman K, Kirchner H, Lochs H, et al. Malnutrition affects quality of life in gastroenterology patients. World J Gastroenterol. 2006;12:3380–3385.
   PubMed Web of Science ®Google Scholar
• Ebadi M, Bhanji RA, Mazurak VC, et al. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol. 2019;54:845–859. Springer Tokyo.
   PubMed Web of Science ®Google Scholar
• Buchard B, Boirie Y, Cassagnes L, et al. Assessment of malnutrition, sarcopenia and frailty in patients with cirrhosis: which tools should we use in clinical practice? Nutrients. 2020;12:186. MDPI AG.
   PubMed Web of Science ®Google Scholar
• Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.
   PubMedGoogle Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.
   PubMed Web of Science ®Google Scholar
• Merli M, Berzigotti A, Zelber-Sagi S, et al. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–193.
   PubMed Web of Science ®Google Scholar
• Dasarathy S. Cause and management of muscle wasting in chronic liver disease. Curr Opin Gastroenterol. 2016;32(3):159–165. Lippincott Williams and Wilkins.
   PubMed Web of Science ®Google Scholar
• Stirnimann G. MEIS. Sarcopenia in patients with cirrhosis is associated with male gender child-pugh class c and inflammation. Hepatology. 2018;68:1173a–1174a.
   Google Scholar
• DiCECCO SR, WIENERS EJ, WIESNER RH, et al. Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. Mayo Clin Proc. 1989;64:95–102.
   PubMed Web of Science ®Google Scholar
• Dasarathy J, McCullough AJ, Dasarathy S. Sarcopenia in alcoholic liver disease: clinical and molecular advances. Alcohol Clin Exp Res. 2017;41:1419–1431. Blackwell Publishing Ltd.
   PubMed Web of Science ®Google Scholar
• Wing SS, Lecker SH, Jagoe RT. Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks. Crit Rev Clin Lab Sci. 2011;48:49–70.
   PubMed Web of Science ®Google Scholar
• Lee JH, Jun H-S. HJ. Role of myokines in regulating skeletal muscle mass and function. Front Physiol. 2019;10:42.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Enomoto H, Ishii A, et al. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle. 2017;8:915–925.
   PubMed Web of Science ®Google Scholar
• Lee K, Ochi E, Song H. EOHS. Activation of AMP-activated protein kinase induce expression of FoxO1, FoxO3a, and myostatin after exercise-induced muscle damage. Biochem Biophys Res Commun. 2015;466:289–294.
   PubMed Web of Science ®Google Scholar
• Assy N, Hochberg Z, Amit T, et al. Growth hormone-stimulated insulin-like growth factor (IGF) I and IGF- binding protein-3 in liver cirrhois. J Hepatol. 1997;27:796–802.
   PubMed Web of Science ®Google Scholar
• Tilg H, Wilmer A, Vogel W. AWWV. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992;103:264–274.
   PubMed Web of Science ®Google Scholar
• Lin SY, Chen W-Y, Lee F-Y. WCFL. Activation of ubiquitin-proteasome pathway is involved in skeletal muscle wasting in a rat model with biliary cirrhosis: potential role of TNF-alpha. Am J Physiol Endocrinol Metab. 2005;288:E493–501.
   PubMed Web of Science ®Google Scholar
• Sandri M, Lin J, Handschin C. JLCH. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA. 2006;103:16260–16265.
   PubMed Web of Science ®Google Scholar
• Shaw R. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol. 2009;196:65–80.
   PubMed Web of Science ®Google Scholar
• Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European association for the study of the liver and the American association for the study of liver diseases. J Hepatol. 2014;61:642–659.
   PubMed Web of Science ®Google Scholar
• Festi D, Ravaioli F, Marasco GCA. Hepatic encephalopathy. Recent Prog Med. 2016 Jul;107(7):378–385.
   PubMedGoogle Scholar
• Dasarathy S, Hatzoglou M. MH. Hyperammonemia and proteostasis in cirrhosis. Curr Opin Clin Nutr Metab Care. 2018;21:30–36.
   PubMed Web of Science ®Google Scholar
• Qiu J, Thapaliya S, Runkana A. STAR. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism. Proc Natl Acad Sci USA. 2013;110:18162–18167.
   PubMed Web of Science ®Google Scholar
• Abrigo J, Elorza AA, Riedel CA. AECR. Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxid Med Cell Longev. 2018;2018:2063179.
   PubMed Web of Science ®Google Scholar
• Davuluri G, Krokowski D, Guan B-J. DKBG. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. J Hepatol. 2016;65:929–937.
   PubMed Web of Science ®Google Scholar
• Qiu J, Tsien C, Thapalaya S. CTST. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012;303:E983–993.
   PubMed Web of Science ®Google Scholar
• Kumar A, Davuluri G, Silva RNE, et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology. 2017;65:2045–2058.
   PubMed Web of Science ®Google Scholar
• Chen H-W, Dunn MA. Muscle at risk: the multiple impacts of ammonia on sarcopenia and frailty in cirrhosis. Clin Transl Gastroenterol. 2016;7:e170.
   PubMed Web of Science ®Google Scholar
• Hayashi F, Matsumoto Y, Momoki C. YMCM. Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis. Hepatol Res. 2013;43:1264–1275.
   PubMed Web of Science ®Google Scholar
• Santos BC, Correia MITD, Anastácio LR. Energy expenditure and liver transplantation: what we know and where we are. J Parenter Enter Nutr. 2020; John Wiley and Sons Inc.. doi:https://doi.org/10.1002/jpen.1985
   Google Scholar
• Ferreira LG, Ferreira Martins AI, Cunha CE, et al. Negative energy balance secondary to inadequate dietary intake of patients on the waiting list for liver transplantation. Nutrition. 2013;29:1252–1258.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Enomoto H, Nishiguchi S, et al. Liver cirrhosis and sarcopenia from the viewpoint of dysbiosis. Int J Mol Sci. 2020;21(15):5254. MDPI AG.
   Web of Science ®Google Scholar
• Baracos VE. LMMK. Cancer-associated cachexia. Nat Rev Dis Prim. 2018;4:17105.
   PubMed Web of Science ®Google Scholar
• Dolz C, Raurich JM, Ibanez J. JRJI. Ascites increases the resting energy expenditure in liver cirrhosis. Gastroenterology. 1991;100:738–744.
   PubMed Web of Science ®Google Scholar
• Chang WK, Chao Y-C, Tang H-S. YCHT. Effects of extra-carbohydrate supplementation in the late evening on energy expenditure and substrate oxidation in patients with liver cirrhosis. JPEN J Parenter Enter Nutr. 1997;21:96–99.
   PubMed Web of Science ®Google Scholar
• Nosadini Aafmcmatedamagrzsdkrtgc R, AVOGARO A, MOLLO F. Carbohydrate and lipid metabolism in cirrhosis. evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow*. J Clin Endocrinol Metab. 1984;58:1125–1132.
   PubMed Web of Science ®Google Scholar
• Petersen KF. MKVN. Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in cirrhosis. Am J Physiol. 1999;276:E529–535.
   PubMedGoogle Scholar
• Tsien C, Davuluri G, Singh D, et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology. 2015;61:2018–2029.
   PubMed Web of Science ®Google Scholar
• Hanai T, Shiraki M, Miwa T. MSTM. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Hepatol Res. 2019;49:82–95.
   PubMed Web of Science ®Google Scholar
• Mandai S, Furukawa S, Kodaka M. SFMK. Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy. Sci Rep. 2017;7:46369.
   PubMed Web of Science ®Google Scholar
• Sinclair M, Grossmann M, Hoermann R, et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. J Hepatol. 2016;65:906–913.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: european consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–423.
   PubMed Web of Science ®Google Scholar
• Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–635.
   PubMed Web of Science ®Google Scholar
• Weijs PJM, Looijaard WGPM, Dekker IM, et al. Low skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill patients. Crit Care. 2014;18(2):R12.
   Google Scholar
• Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transplant. 2012;18:1209–1216.
   PubMed Web of Science ®Google Scholar
• Hanai T, Shiraki M, Nishimura K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 2015;31:193–199.
   PubMed Web of Science ®Google Scholar
• Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.
   PubMed Web of Science ®Google Scholar
• Abrams HL, Mcneil BJ. Medical implications of computed tomography (cat scanning). N Engl J Med N Engl J Med. 1978;298:255–261.
   PubMedGoogle Scholar
• Shen W, Punyanitya M, Wang ZM, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97:2333–2338.
   PubMed Web of Science ®Google Scholar
• Moisey LL, Mourtzakis M, Cotton BA, et al. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. Crit Care. 2013;17(5):R206.
   Web of Science ®Google Scholar
• Braunschweig CA, Sheean PM, Peterson SJ, et al. Exploitation of diagnostic computed tomography scans to assess the impact of nutrition support on body composition changes in respiratory failure patients. J Parenter Enter Nutr. 2014;38:880–885.
   PubMed Web of Science ®Google Scholar
• Sheean PM, Peterson SJ, Gomez Perez S, et al. The prevalence of sarcopenia in patients with respiratory failure classified as normally nourished using computed tomography and subjective global assessment. J Parenter Enter Nutr. 2014;38:873–879.
   PubMed Web of Science ®Google Scholar
• Lieffers JR, Bathe OF, Fassbender K, et al. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012;107:931–936.
   PubMed Web of Science ®Google Scholar
• Tan BHL, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009 [cited 2020 Mar 23];15:6973–6979. Internet]. Available from. : http://www.ncbi.nlm.nih.gov/pubmed/19887488
   PubMed Web of Science ®Google Scholar
• Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85:115–122.
   PubMed Web of Science ®Google Scholar
• Gomez-Perez SL, Haus JM, Sheean P, et al. Measuring abdominal circumference and skeletal muscle from a single cross-sectional computed tomography image: A step-by-step guide for clinicians using National Institutes of Health ImageJ. J Parenter Enter Nutr. 2016;40:308–318.
   PubMed Web of Science ®Google Scholar
• Durand F, Buyse S, Francoz C, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol. 2014;60:1151–1157.
   PubMed Web of Science ®Google Scholar
• Tosato M, Marzetti E, Cesari M, et al. Measurement of muscle mass in sarcopenia: from imaging to biochemical markers. Aging Clin Exp Res. 2017;29:19–27.
   PubMed Web of Science ®Google Scholar
• Mayans D, Cartwright MS, Walker FO. Neuromuscular ultrasonography: quantifying muscle and nerve measurements. Phys Med Rehabil Clin N Am Phys Med Rehabil Clin N Am. 2012;23:133–148.
   PubMed Web of Science ®Google Scholar
• Pirlich M, Schütz T, Spachos T, et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology. 2000;32:1208–1215.
   PubMed Web of Science ®Google Scholar
• Ruiz-Margáin A, Macías-Rodríguez RU, Duarte-Rojo A, et al. Malnutrition assessed through phase angle and its relation to prognosis in patients with compensated liver cirrhosis: a prospective cohort study. Dig Liver Dis. 2015 [cited 2020 Oct 28];47:309–314. Internet]. Available from: https://pubmed.ncbi.nlm.nih.gov/25618555/
   PubMedGoogle Scholar
• Sinclair M, Chapman B, Hoermann R, et al. Handgrip strength adds more prognostic value to the model for end-stage liver disease score than imaging-based measures of muscle mass in men with cirrhosis. Liver Transplant. 2019;25:1480–1487.
   PubMed Web of Science ®Google Scholar
• van Vugt JLA, Buettner S, Alferink LJM, et al. Low skeletal muscle mass is associated with increased hospital costs in patients with cirrhosis listed for liver transplantation–a retrospective study. Transpl Int. 2018;31:165–174.
   PubMed Web of Science ®Google Scholar
• van Vugt JLA, Levolger S, de Bruin RWF, et al. Systematic review and meta-analysis of the impact of computed tomography–assessed skeletal muscle mass on outcome in patients awaiting or undergoing liver transplantation. Am J Transplant. 2016;16:2277–2292. Blackwell Publishing Ltd .
   PubMed Web of Science ®Google Scholar
• Paternostro R, Lampichler K, Bardach C, et al. The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. Liver Int. 2019;39:2374–2385.
   PubMed Web of Science ®Google Scholar
• Yao J, Zhou X, Yuan L, et al. Prognostic value of the third lumbar skeletal muscle mass index in patients with liver cirrhosis and ascites. Clin Nutr. 2019;39(6):1908-1913.
   Web of Science ®Google Scholar
• Moctezuma-Velazquez C, Ebadi M, Bhanji RA, et al. Limited performance of subjective global assessment compared to computed tomography-determined sarcopenia in predicting adverse clinical outcomes in patients with cirrhosis. Clin Nutr. 2019;38:2696–2703.
   PubMed Web of Science ®Google Scholar
• Montano-Loza AJ, Duarte-Rojo A, Meza-Junco J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol. 2015;6:e102–8. [Internet].
   PubMed Web of Science ®Google Scholar
• van Vugt JLA, Alferink LJM, Buettner S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. J Hepatol. 2018;68:707–714.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–1547.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Shiraki M, Hiramatsu A, et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016;46:951–963.
   PubMed Web of Science ®Google Scholar
• Carey EJ, Lai JC, Wang CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transplant. 2017;23:625–633.
   PubMed Web of Science ®Google Scholar
• Welch N, Dasarathy J, Runkana A, et al. Continued muscle loss increases mortality in cirrhosis: impact of aetiology of liver disease. Liver Int. 2019;40(5):1178-1188.
   Web of Science ®Google Scholar
• Hari A, Berzigotti A, Štabuc B, et al. Muscle psoas indices measured by ultrasound in cirrhosis — preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality. Dig Liver Dis. 2019;51:1502–1507.
   PubMedGoogle Scholar
• Gu DH, Kim MY, Seo YS, et al. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. Clin Mol Hepatol. 2018;24(3):319–330.
   PubMed Web of Science ®Google Scholar
• Huguet A, Latournerie M, Debry PH, et al. The psoas muscle transversal diameter predicts mortality in patients with cirrhosis on a waiting list for liver transplantation: a retrospective cohort study. Nutrition. 2018;51–52:73–79.
   PubMed Web of Science ®Google Scholar
• Kim TY, Kim MY, Sohn JH, et al. Sarcopenia as a useful predictor for long-term mortality in cirrhotic patients with ascites. J Korean Med Sci. 2014;29:1253–1259.
   PubMed Web of Science ®Google Scholar
• Baracos VE. Psoas as a sentinel muscle for sarcopenia: a flawed premise. J Cachexia Sarcopenia Muscle. 2017;8:527–528. Wiley Blackwell.
   PubMed Web of Science ®Google Scholar
• Ebadi M, Wang CW, Lai JC, et al. Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis. J Cachexia Sarcopenia Muscle. 2018;9:1053–1062.
   PubMed Web of Science ®Google Scholar
• Lai JC, Dodge JL, Sen S, et al. Functional decline in patients with cirrhosis awaiting liver transplantation: results from the functional assessment in liver transplantation (FrAILT) study. Hepatology. 2016;63:574–580.
   PubMed Web of Science ®Google Scholar
• Wang CW, Feng S, Covinsky KE, et al. A comparison of muscle function, mass, and quality in liver transplant candidates: results from the functional assessment in liver transplantation study. Transplantation. 2016;100:1692–1698.
   PubMed Web of Science ®Google Scholar
• Daphnee DK, John S, Vaidya A, et al. Hand grip strength: A reliable, reproducible, cost-effective tool to assess the nutritional status and outcomes of cirrhotics awaiting liver transplant. Clin Nutr ESPEN. 2017;19:49–53.
   Web of Science ®Google Scholar
• Belarmino G, Gonzalez MC, Sala P, et al. Diagnosing sarcopenia in male patients with cirrhosis by dual-energy x-ray absorptiometry estimates of appendicular skeletal muscle mass. J Parenter Enter Nutr. 2018;42:24–36.
   PubMed Web of Science ®Google Scholar
• Hanai T, Shiraki M, Imai K, et al. Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: A sex-stratified analysis. Hepatol Res. 2019;49:1414–1426.
   PubMed Web of Science ®Google Scholar
• Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with liver cirrhosis. Nutrition. 2001;17:445–450.
   PubMed Web of Science ®Google Scholar
• Carey EJ, Steidley DE, Aqel BA, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transplant. 2010;16:1373–1378.
   PubMed Web of Science ®Google Scholar
• Yadav A, Chang YH, Carpenter S, et al. Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. Clin Transplant. 2015;29:134–141.
   PubMed Web of Science ®Google Scholar
• Lai JC, Rahimi RS, Verna EC, et al. Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study. Gastroenterology. 2019;156:1675–1682.
   PubMed Web of Science ®Google Scholar
• Lai JC, Feng S, Terrault NA, et al. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant. 2014;14:1870–1879.
   PubMed Web of Science ®Google Scholar
• Rodrigues SG, Brabandt B, Stirnimann G, et al. Adipopenia correlates with higher portal pressure in patients with cirrhosis. Liver Int. 2019;39(9):1672-1681.
   Web of Science ®Google Scholar
• Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7:126–135.
   PubMed Web of Science ®Google Scholar
• Lattanzi B, Nardelli S, Pigliacelli A, et al. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease. Dig Liver Dis. 2019;51:1508–1512.
   PubMedGoogle Scholar
• Jeong JY, Lim S, Sohn JH, et al. Presence of sarcopenia and its rate of change are independently associated with long-term mortality in patients with liver cirrhosis. J Korean Med Sci. 2018;33(50):e299.
   Web of Science ®Google Scholar
• Hanai T, Shiraki M, Ohnishi S, et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res. 2016;46:743–751.
   PubMed Web of Science ®Google Scholar
• Ebadi M, Tandon P, Moctezuma-Velazquez C, et al. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis. J Hepatol. 2018;69:608–616.
   PubMed Web of Science ®Google Scholar
• Kalafateli M, Karatzas A, Tsiaoussis G, et al. Muscle fat infiltration assessed by total psoas density on computed tomography predicts mortality in cirrhosis. Ann Gastroenterol. 2018;31:491–498.
   PubMed Web of Science ®Google Scholar
• D’Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39:1180–1193.
   PubMed Web of Science ®Google Scholar
• Kang SH, Jeong WK, Baik SK, et al. Impact of sarcopenia on prognostic value of cirrhosis: going beyond the hepatic venous pressure gradient and MELD score. J Cachexia Sarcopenia Muscle. 2018;9:860–870.
   PubMed Web of Science ®Google Scholar
• Lattanzi B, D’Ambrosio D, Merli M. Hepatic encephalopathy and sarcopenia: two faces of the same metabolic alteration. J Clin Exp Hepatol. 2019;9:125–130. Elsevier B.V..
   PubMed Web of Science ®Google Scholar
• Merli M, Giusto M, Lucidi C, et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis. 2013;28:281–284.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Lattanzi B, Merli M, et al. Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis. Hepatology. 2019;70:1704–1713.
   PubMed Web of Science ®Google Scholar
• Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int. 2018;12:377–386.
   PubMed Web of Science ®Google Scholar
• Hanai T, Shiraki M, Watanabe S, et al. Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis. Hepatol Res. 2017;47:1359–1367.
   PubMed Web of Science ®Google Scholar
• Oey RC, Aarts P, Erler NS, et al. Identification and prognostic impact of malnutrition in a population screened for liver transplantation. Clin Nutr ESPEN. 2020;36:36–44.
   PubMed Web of Science ®Google Scholar
• Lattanzi B, Gioia S, Di Cola S, et al. Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. Liver Int. 2019;39:1937–1942.
   PubMed Web of Science ®Google Scholar
• Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list. Transplantation. 2020;104(7):e188-e198.
   PubMedGoogle Scholar
• Gioia S, Merli M, Nardelli S, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver Int. 2019;39:871–877.
   PubMed Web of Science ®Google Scholar
• Tsien C, Shah SN, Mccullough AJ, et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent. Eur J Gastroenterol Hepatol. 2013;25:85–93.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol. 2017;15:934–936.
   PubMed Web of Science ®Google Scholar
• Álvares-Da-Silva MR, Reverbel Da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition. 2005;21:113–117.
   PubMed Web of Science ®Google Scholar
• Praktiknjo M, Clees C, Pigliacelli A, et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Clin Transl Gastroenterol. 2019;10(4):e00025.
   Web of Science ®Google Scholar
• Praktiknjo M, Book M, Luetkens J, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. Hepatology. 2018;67:1014–1026.
   PubMed Web of Science ®Google Scholar
• Shoreibah MG, Mahmoud K, Aboueldahab NA, et al. Psoas muscle density in combination with model for end-stage liver disease score can improve survival predictability in transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2019;30:154–161.
   PubMed Web of Science ®Google Scholar
• Marasco G, Serenari M, Renzulli M, et al. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. J Gastroenterol. 2020;55(10):927-943.
   PubMed Web of Science ®Google Scholar
• Harimoto N, Shirabe K, Yamashita YI, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013;100:1523–1530.
   PubMed Web of Science ®Google Scholar
• Levolger S, Van Vledder MG, Muslem R, et al. Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinoma. J Surg Oncol. 2015;112:208–213.
   PubMed Web of Science ®Google Scholar
• Iritani S, Imai K, Takai K, et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol. 2015;50:323–332.
   PubMed Web of Science ®Google Scholar
• Itoh S, Shirabe K, Matsumoto Y, et al. Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. Ann Surg Oncol. 2014;21:3063–3068.
   PubMed Web of Science ®Google Scholar
• Kamachi S, Mizuta T, Otsuka T, et al. Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepatol Res. 2016;46:201–208.
   PubMed Web of Science ®Google Scholar
• Meza-Junco J, Montano-Loza AJ, Baracos VE, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol. 2013;47:861–870.
   PubMed Web of Science ®Google Scholar
• Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7:1–7.
   Web of Science ®Google Scholar
• Yamashima M, Miyaaki H, Honda T, et al. Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib. Mol Clin Oncol. 2017;7:449–453.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Nishijima N, Enomoto H, et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett. 2017;14:1637–1647.
   PubMed Web of Science ®Google Scholar
• Antonelli G, Gigante E, Iavarone M, et al. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United Eur Gastroenterol J. 2018;6:1039–1048.
   PubMed Web of Science ®Google Scholar
• Feng Z, Zhao H, Jiang Y, et al. Sarcopenia associates with increased risk of hepatocellular carcinoma among male patients with cirrhosis. Clin Nutr. 2020;39:3132–3139.
   Web of Science ®Google Scholar
• Tachi Y, Kozuka A, Hirai T, et al. Skeletal muscle fat deposition is associated with hepatocellular carcinoma development in patients with chronic liver disease. Nutrition. 2018;54:83–88.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Enomoto H, Yoh K, et al. Association between sarcopenia and depression in patients with chronic liver diseases. J Clin Med. 2019;8:634.
   Web of Science ®Google Scholar
• Nishikawa H, Enomoto H, Yoh K, et al. Effect of sarcopenia on sleep disturbance in patients with chronic liver diseases. J Clin Med. 2018;8:16.
   Web of Science ®Google Scholar
• Hiraoka A, Tamura R, Oka M, et al. Prediction of risk of falls based on handgrip strength in chronic liver disease patients living independently. Hepatol Res. 2019;49:823–829.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Ishikawa T, Imai M, et al. Relationship between pre-sarcopenia and quality of life in patients with chronic liver disease: A cross-sectional study. Eur J Gastroenterol Hepatol. 2019;31:1408–1413.
   PubMed Web of Science ®Google Scholar
• Ando Y, Ishigami M, Ito T, et al. Sarcopenia impairs health-related quality of life in cirrhotic patients. Eur J Gastroenterol Hepatol. 2019;31:1550–1556.
   PubMed Web of Science ®Google Scholar